Amgen Inc. is hot on the heels of Regeneron Pharmaceuticals Inc., reporting that its monoclonal antibody targeting PCSK9, evolocumab, reduced low-density lipoprotein cholesterol (LDL-C) in a 12-week Phase III trial.